Search research articles
Contact Us
Filters
Showing results (31-40 of 162) with videos related to
Page
of 17
Sort By:
Clinicoeconomics and Outcomes Research : CEOR
|
June 1, 2013
Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain
Josep M Llibre, Gloria Cardona, José R Santos, et al.
Journal of the International AIDS Society
|
November 14, 2014
Hidden costs of HIV treatment in Spain: inefficiency of the antiretroviral drug packaging
Josep M Llibre-Codina, Angels Andreu-Crespo, Gloria Cardona-Peitx, et al.
AIDS (London, England)
|
September 29, 2012
Platelet count kinetics following interruption of antiretroviral treatment
Eva Zetterberg, Jacqueline Neuhaus, Jason V Baker, et al.
AIDS Research and Human Retroviruses
|
July 28, 2011
Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice
Gabriel Vallecillo, Pere Domingo, Josep Mallolas, et al.
Plos One
|
July 9, 2016
Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
Josep M Llibre, François Raffi, Graeme Moyle, et al.
Plos One
|
June 25, 2015
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia
Josep M Llibre, Isabel Bravo, Arelly Ornelas, et al.
Plos One
|
February 13, 2016
EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment
Björn Vandewalle, Josep M Llibre, Jean-Jacques Parienti, et al.
The Journal of Antimicrobial Chemotherapy
|
March 11, 2022
Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression
Boris Revollo, Laura Viñuela, Lorena de la Mora, et al.
HIV Medicine
|
March 2, 2022
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
Hortensia Álvarez, Marta Rava, Cristina Martínez, et al.
Current HIV Research
|
May 18, 2012
Effectiveness of antiretroviral therapy in HIV-1-infected active drug users attended in a drug abuse outpatient treatment facility providing a multidisciplinary care strategy
Gabriel V Sánchez, Josep M Llibre, Marta Torrens, et al.
Page
of 17
Search research articles
Search
Showing results (31-40 of 162) with videos related to
Sort By:
Page
of 17
Clinicoeconomics and Outcomes Research : CEOR
|
June 1, 2013
Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain
Josep M Llibre, Gloria Cardona, José R Santos, et al.
Journal of the International AIDS Society
|
November 14, 2014
Hidden costs of HIV treatment in Spain: inefficiency of the antiretroviral drug packaging
Josep M Llibre-Codina, Angels Andreu-Crespo, Gloria Cardona-Peitx, et al.
AIDS (London, England)
|
September 29, 2012
Platelet count kinetics following interruption of antiretroviral treatment
Eva Zetterberg, Jacqueline Neuhaus, Jason V Baker, et al.
AIDS Research and Human Retroviruses
|
July 28, 2011
Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice
Gabriel Vallecillo, Pere Domingo, Josep Mallolas, et al.
Plos One
|
July 9, 2016
Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
Josep M Llibre, François Raffi, Graeme Moyle, et al.
Plos One
|
June 25, 2015
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia
Josep M Llibre, Isabel Bravo, Arelly Ornelas, et al.
Plos One
|
February 13, 2016
EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment
Björn Vandewalle, Josep M Llibre, Jean-Jacques Parienti, et al.
The Journal of Antimicrobial Chemotherapy
|
March 11, 2022
Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression
Boris Revollo, Laura Viñuela, Lorena de la Mora, et al.
HIV Medicine
|
March 2, 2022
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
Hortensia Álvarez, Marta Rava, Cristina Martínez, et al.
Current HIV Research
|
May 18, 2012
Effectiveness of antiretroviral therapy in HIV-1-infected active drug users attended in a drug abuse outpatient treatment facility providing a multidisciplinary care strategy
Gabriel V Sánchez, Josep M Llibre, Marta Torrens, et al.
Page
of 17